Eli Lilly hits another Alzheimer’s hurdle. But obesity, diabetes GLP-1s strong
Eli Lilly ‘s experimental Alzheimer’s treatment hit another hurdle with U.S. drug regulators. It pushed out the timeline for potential approval but did not rattle our investment thesis in the …